Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
10.58
-0.52 (-4.68%)
Aug 20, 2026, 10:05 AM EDT - Market open
Keros Therapeutics Revenue
Keros Therapeutics had revenue of $15.01M in the twelve months ending June 30, 2026, down -93.55% year-over-year. In the year 2025, Keros Therapeutics had annual revenue of $244.06M with 6,774.96% growth.
Revenue (ttm)
$15.01M
Revenue Growth
-93.55%
P/S Ratio
14.66
Revenue / Employee
$163,196
Employees
92
Market Cap
209.77M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 244.06M | 240.51M | 6,774.96% |
| Dec 31, 2024 | 3.55M | 3.40M | 2,250.99% |
| Dec 31, 2023 | 151.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 20.10M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 10.00M | - | - |
| Dec 31, 2018 | 10.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
KROS News
- 9 days ago - Keros Therapeutics price target lowered to $17 from $20 at BofA - TheFly
- 16 days ago - Keros Therapeutics price target lowered to $18 from $20 at Wells Fargo - TheFly
- 16 days ago - Keros Therapeutics price target lowered to $23 from $30 at Leerink - TheFly
- 16 days ago - Keros Therapeutics reports Q2 EPS ($1.45), consensus ($1.24) - TheFly
- 16 days ago - Keros Therapeutics Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 16 days ago - Keros Therapeutics Earnings release: Q2 2026 - Filings
- 16 days ago - Keros Therapeutics Quarterly report: Q2 2026 - Filings
- 20 days ago - Keros Therapeutics to receive $20M elritercept milestone payment from Takeda - TheFly